Generated by AI
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for immune-mediated inflammatory diseases. The company’s current work centers on IL-1β-based treatments, with Abdakibart (AVTX-009) as its lead asset, an anti-IL-1β monoclonal antibody designed to address inflammatory conditions. Avalo Therapeutics also maintains a pipeline that includes additional immune-focused programs, reflecting its emphasis on targeting dysregulated inflammation through biologic therapies. Based in Wayne, Pennsylvania, and incorporated in 2011, the company operates within the immunology and inflammation space, where its products are aimed at diseases with significant unmet medical need.
Website1500 Liberty Ridge Drive
Wayne, PA, 19087
United States
The latest articles about AVTX.
Avalo Therapeutics (AVTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
WAYNE, Pa., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences: Guggenheim Healthcare Innovation ConferenceFireside ChatNovember 9, 2026 at 8:30am ET Stifel 2026 Healthcare ConferenceFireside ChatNovember 10, 2026 at 2:00pm ET Live webcasts a
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Summary of Oct 23's posts. Generated by AI.
Summary of Oct 22's posts. Generated by AI.
Summary of Oct 23's posts. Generated by AI.
Investors talking about AVTX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.